Xintela granted 1 million SEK from Vinnova
Lund, Sweden, May 8, 2020 – Xintela has been granted 1 million SEK from Vinnova in the call for “ Innovations in the wake of the crisis – Restructuring of society, operations and production in the wake of the corona epidemic.”. The grant concerns the funding of a preclinical study to evaluate Xintela’s stem cells […]
Xintela granted 2 million SEK from Vinnova
Lund, Sweden, March 27, 2020 – Xintela has been granted 2 million SEK from Vinnova in the call for “Innovation projects in small and medium-sized companies”. The grant concerns one of the company’s cancer projects and the work to develop targeted therapies for aggressive cancers with integrin 10-binding ADCs. “This is very good news for […]
Xintela publishes positive preclinical results from equine study
Lund, Sweden, 3 February, 2020 – Xintela announces that the results from the company’s stem cell study on horses has now been published in the respected scientific journal The American Journal of Sports Medicine. The publication demonstrates that the stem cell treatment is safe and that it has a significantly positive effect on both cartilage […]
Xintela publishes results from glioblastoma study
Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company’s glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela’s marker, integrin a10b1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the […]
Xintela appoints Sven Kili as Chief Operating Officer
Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience […]
Xintela and Catalent to co-develop brain cancer therapy
Lund, Sverige, 25 oktober 2018 – Xintela tillkännager idag att bolaget har tecknat ett samarbetsavtal med det amerikanska bolaget Redwood BioScience Inc, ett helägt dotterbolag till Catalent, Inc., världsledande inom antibody-drug conjugate (ADC) teknologi för cancerterapi. Parterna avser att gemensamt utveckla en ADC-baserad terapeutisk produkt med första inriktning på hjärntumören glioblastom, den vanligaste och mest […]
SVEN KILI TAKES ROLE AS CHIEF MEDICAL OFFICER IN XINTELA
Lund, Sweden, August 29, 2018 – Xintela AB (publ) announces today that Sven Kili extends his commitment to Xintela as Chief Medical Officer (CMO). Sven Kili, a board member and consultant to Xintela, extends his commitment to Xintela as CMO on a consultancy basis. Sven is a physician and specialist in orthopedics and, through leading […]
Xintela to collaborate with Japanese CellSeed Inc.
Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint. “It is very exciting that we have established a collaboration in Japan which, due to a […]
Xintela signs memorandum of understanding with CO.DON
Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela’s quality markers for CO.DON’s next cell-based product and for the co- development of Xintela’s stem cell product for the treatment of osteoarthritis. […]
Xintela receives 1,5 MSEK in dispute settlement
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]
